Procept Biorobotics Financials

PRCT Stock  USD 68.11  5.40  8.61%   
Based on the key indicators related to Procept Biorobotics' liquidity, profitability, solvency, and operating efficiency, Procept Biorobotics Corp is not in a good financial situation at this time. It has a very high probability of going through financial hardship in March. At this time, Procept Biorobotics' Non Currrent Assets Other are comparatively stable compared to the past year. Net Receivables is likely to gain to about 58.4 M in 2025, whereas Net Debt is likely to drop (168.2 M) in 2025. Key indicators impacting Procept Biorobotics' financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio8.086.87
Fairly Up
Pretty Stable
The essential information of the day-to-day investment outlook for Procept Biorobotics includes many different criteria found on its balance sheet. An individual investor should monitor Procept Biorobotics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Procept Biorobotics.

Net Income

(100.07 Million)

  

Procept Biorobotics Corp Earnings Geography

Please note, the imprecision that can be found in Procept Biorobotics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Procept Biorobotics Corp. Check Procept Biorobotics' Beneish M Score to see the likelihood of Procept Biorobotics' management manipulating its earnings.

Procept Biorobotics Stock Summary

Procept Biorobotics competes with Orthopediatrics Corp, Neuropace, Pulmonx Corp, SurModics, and Orthofix Medical. PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California. Procept Biorobotics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 234 people.
Specialization
Health Care, Health Care Equipment & Services
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS74276L1052
CUSIP74276L105
LocationCalifornia; U.S.A
Business Address150 Baytech Drive,
SectorHealth Care Equipment & Supplies
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.procept-biorobotics.com
Phone650 232 7200
CurrencyUSD - US Dollar

Procept Biorobotics Key Financial Ratios

Procept Biorobotics Key Balance Sheet Accounts

202020212022202320242025 (projected)
Total Assets126.0M337.0M309.3M404.7M465.4M272.6M
Other Current Liab6.5M8.5M20.1M23.4M26.9M28.2M
Net Debt(45.4M)(250.2M)(144.5M)(178.0M)(160.2M)(168.2M)
Retained Earnings(201.7M)(261.5M)(348.7M)(454.6M)(409.1M)(429.6M)
Accounts Payable1.2M2.0M9.4M13.5M15.5M16.3M
Cash100.1M304.3M221.9M257.2M295.8M203.6M
Long Term Debt44.4M50.0M51.2M51.3M59.0M48.4M
Net Receivables1.5M4.5M15.3M48.4M55.6M58.4M
Inventory7.5M13.1M28.5M39.8M45.7M48.0M
Other Current Assets1.1M6.8M7.0M5.2M6.0M4.6M
Total Liab308.9M69.9M112.3M124.0M111.6M131.3M
Net Invested Capital(133.9M)317.1M248.3M332.1M381.9M401.0M
Total Current Assets110.3M326.2M272.6M350.6M403.2M244.3M
Net Working Capital95.7M309.9M237.3M304.6M350.3M218.1M
Short Term Debt6.3M4.2M2.1M3.4M3.1M3.1M
Intangible Assets2.0M1.8M1.5M1.2M1.1M1.4M

Procept Biorobotics Key Income Statement Accounts

The reason investors look at the income statement is to determine what Procept Biorobotics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
202020212022202320242025 (projected)
Net Interest Income(5.1M)(5.7M)(2.7M)1.8M2.1M2.2M
Interest Income184K121K2.5M5.6M6.4M6.7M
Interest Expense5.3M5.8M5.2M4.0M4.6M4.6M
Total Revenue7.7M34.5M75.0M136.2M156.6M164.5M
Gross Profit(1.3M)15.9M37.1M71.0M81.7M85.8M
Operating Income(47.8M)(54.2M)(80.7M)(109.2M)(98.3M)(103.2M)
Ebit(47.8M)(54.0M)(82.0M)(101.9M)(91.7M)(96.3M)
Research Development16.3M19.0M29.0M48.4M55.7M58.5M
Ebitda(45.1M)(51.1M)(77.7M)(98.1M)(88.3M)(92.7M)
Cost Of Revenue9.0M18.6M37.9M65.1M74.9M78.7M
Income Before Tax(53.0M)(59.9M)(87.2M)(105.9M)(95.3M)(100.1M)
Net Income(58.3M)(62.4M)(93.6M)(105.9M)(95.3M)(100.1M)
Income Tax Expense5.2M2.5M6.4M3.6M4.2M4.1M

Procept Biorobotics Key Cash Accounts

202020212022202320242025 (projected)
Change To Inventory(3.1M)(6.1M)(15.3M)(9.8M)(8.8M)(9.2M)
Investments(233K)(592K)(2.7M)(17.4M)(15.6M)(14.8M)
Change In Cash58.2M204.2M(79.4M)34.6M31.1M38.9M
Free Cash Flow(48.6M)(57.9M)(83.0M)(133.2M)(119.9M)(113.9M)
Depreciation2.9M3.3M2.8M3.8M4.4M3.2M
Other Non Cash Items(97K)(345K)5.1M1.1M1.3M870.1K
Capital Expenditures233K592K2.7M25.2M29.0M30.4M
Net Income(53.0M)(59.9M)(87.2M)(105.9M)(95.3M)(100.1M)
End Period Cash Flow100.9M305.1M225.7M260.3M299.3M205.6M

Procept Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Procept Biorobotics's current stock value. Our valuation model uses many indicators to compare Procept Biorobotics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Procept Biorobotics competition to find correlations between indicators driving Procept Biorobotics's intrinsic value. More Info.
Procept Biorobotics Corp is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Procept Biorobotics' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Procept Biorobotics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Procept Biorobotics Corp Systematic Risk

Procept Biorobotics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Procept Biorobotics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Procept Biorobotics Corp correlated with the market. If Beta is less than 0 Procept Biorobotics generally moves in the opposite direction as compared to the market. If Procept Biorobotics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Procept Biorobotics Corp is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Procept Biorobotics is generally in the same direction as the market. If Beta > 1 Procept Biorobotics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Procept Biorobotics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Procept Biorobotics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Procept Biorobotics growth as a starting point in their analysis.

Price Earnings To Growth Ratio

(3.67)

At this time, Procept Biorobotics' Price Earnings To Growth Ratio is comparatively stable compared to the past year.

Procept Biorobotics February 27, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Procept Biorobotics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Procept Biorobotics Corp. We use our internally-developed statistical techniques to arrive at the intrinsic value of Procept Biorobotics Corp based on widely used predictive technical indicators. In general, we focus on analyzing Procept Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Procept Biorobotics's daily price indicators and compare them against related drivers.

Additional Tools for Procept Stock Analysis

When running Procept Biorobotics' price analysis, check to measure Procept Biorobotics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Procept Biorobotics is operating at the current time. Most of Procept Biorobotics' value examination focuses on studying past and present price action to predict the probability of Procept Biorobotics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Procept Biorobotics' price. Additionally, you may evaluate how the addition of Procept Biorobotics to your portfolios can decrease your overall portfolio volatility.